Allergen-specific immunosuppression by ovalbumin fused with diphtheria toxin in mice sensitized with albumins of different origin

Clinical and Experimental Allergy

Volumn 34, Issue 10, 2004, Pages 1642-1648

  Lee, Bong Ki ^a   Yoo, J E ^a   Jang, Y S ^a   Kim, J Y ^a   Hong, C S ^a   Ro, J Y ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Allergen toxin fusion protein; Diphtheria toxin; Immunotherapy; Ovalbumin

Indexed keywords

ALBUMIN; ALLERGEN; DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; OVALBUMIN; TOXIN;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TARGET CELL;

ALBUMINS; ALLERGENS; ANAPHYLAXIS; ANIMALS; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DIPHTHERIA TOXIN; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; OVALBUMIN; SERUM ALBUMIN;

EID: 6344237240     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02077.x     Document Type: Article

References (32)

1. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91:709-22.
2. Orfan NA, Dykewicz MS, Bamowsky L. Extensive subcutaneous fibrosis in a patient treated with alum precipitated allergenic extract. Ann Allergy Asthma Immunol 1995; 75:453-6.
3. Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R. Safety and immunogenicity of immunotherapy with accelerated dosage schedules of polymerized grass and short ragweed in patients with dual inhalant sensitivity. J Allergy Clin Immunol 1989; 83:750-6.
4. Norman PS, Ohman JL Jr, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-8.
5. Haselden BM, Kay AB, Larche M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 2000; 122:229-37.
6. Lewis DB. Allergy immunotherapy and inhibition of Th2 immune responses: a sufficient strategy? Curr Opm Immunol 2002; 14:644-51.
7. Kagi MK, Wuthrich B. Different methods of local allergen-specific immunotherapy. Allergy 2002; 57:379-88.
8. Nopp A, Hallden G, Lundahl J et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen allergic patients. J Allergy Clin Immunol 2000; 106:101-9.
9. Tamura S, Hatori E, Tsuruhara T, Aizawa C, Kurata T. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Eschrichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine 1997; 15:225-9.
10. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient trans mucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994; 91:10795-9.
11. Rask C, Holmgren J, Fredriksson M et al. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Clin Exp Allergy 2000; 30:1024-32.
12. Wiedermann U, Jahn-Schmid B, Lindblad M et al. Suppressive vs. stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I. Allergy 1999; 11:1717-24.
13. Lustgarten J, Waks T, Eshhar Z. Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. Mol Immunol 1996; 33:245-51.
14. Slater JE, Boltansky H, Kaliner M. IgE immunotoxins. Effect of an IgE-ricin A chain conjugate on rat skin histamine content. J Immunol 1988; 140:807-11.
15. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997; 158:4137-44.
16. Lee BK, Yoo YG, Lee WY, Hong CH, Park JK, Ro JY. Ovalbumin fused with diphtheria toxin protects mice from ovalbumin-induced anaphylactic shock. Yonsei Med J 2001; 42:91-105.
17. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5:387-91.
18. Hirano T, Yamakawa N, Miyajima H et al. An improved method for the detection of IgE antibody of defined specificity by ELISA using rat monoclonal anti-IgE antibody. J Immunol Methods 1989; 119:145-50.
19. Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current protocols in immunology, Vol. 1. New York: John Wiley & Sons, Inc., 1998; 3.0.1-3.1.5.
20. Secrist H, Chelen CJ, Wen Y, Marshall DJ, Umetus D. Allergen immunotherapy decreases interleukin-4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178:2123-30.
21. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee-venom immunotherapy results in decrease of IL-4 and IL-5 and increase IFN-γ secretion in specific allergen-stimulated T-cell culture. J Immunol 1995; 154:4187-94.
22. Gabrielsson S. Specific immunotherapy prevents increased levels of allergen-specific IL-4 and IL-13-producing cells during pollen season. Allergy 2001; 56:293-300.
23. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee-venom immunotherapy induces a shift in cytokine response from a Th2 to a Th1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1996; 25:828-38.
24. Ebner C, Siemann U, Bohle B et al. Immunological change during specific immunotherapy of grass-pollen allergy reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phi p 1, a major grass-pollen allergen. Clin Exp Allergy 1997; 27:1007-15.
25. Toda M, Ono SJ. Genomics and proteomics of allergic disease. Immunology 2002; 106:1-10.
26. Watanabe M, Wegma DR, Ochi A, Hozumi N. Antigen presentation by a B-cell line transfected with cloned immunoglobulin heavy- and light-chain genes specific for a defined hapten. Proc Natl Acad Sci USA 1986; 83:5247-51.
27. Miettinen HM, Rose JK, Mellman I. Fc receptor isoforms exhibit distinct abilities for coated pit localization as a result of cytoplasmic domain heterogeneity. Cell 1989; 58:317-27.
28. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985; 314:537-9.
29. Kehry MR, Yamashita LC. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Natl Acad Sci USA 1989; 86:7556-60.
30. Mudde GC, Hansel TT, Reijsen FCv, Osterhoff BF, Bruijnzeel-Koomen CAFM. IgE: an immunoglobulin specialized in antigen capture? Immunol Today 1990; 11:440-3.
31. Lanzavecchia A. Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev 1987; 99:39-51.
32. Casten LA, Pierce SK. Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures. J Immunol 1988; 140:404-10.